Our results are also in accordance with a study performed in colorectal cancer reporting that loss of SOX9 expression in the invasive front of the tumours predicts tumour relapse in stage II colon cancer patients [15], although the prognostic value of SOX9 is also not consensual in colorectal cancer [22, 23]. This evidence concerns the gene SOX9 and malignant colon neoplasm.